Baxter International | BAX - Equity Capital And Reserves


Baxter International reported $6.04B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
AngioDynamics USD 176.33M 2.52M Sep/2025
Artivion USD 450.47M 2.24M Mar/2026
AtriCure USD 491.69M 242K Mar/2026
Avanos Medical USD 782.1M 3.9M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Dexcom USD 2.96B 210.9M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Fresenius EUR 19.77B 1.14B Dec/2025
Globus Medical USD 4.73B 159.06M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
ICU Medical USD 2.11B 11.9M Mar/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.3B 212.6M Mar/2026
Integra LifeSciences USD 1.04B 1.06M Mar/2026
Intuitive Surgical USD 17.47B 349.5M Mar/2026
J&J USD 81.19B 358M Mar/2026
Laboratory Of America USD 8.73B 108.8M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Quest Diagnostics USD 7.37B 196M Mar/2026
Smith & Nephew USD 5.54B 331M Dec/2025
Stryker USD 22.42B 635M Dec/2025
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
Terumo JPY 1.58T 62.18B Mar/2026
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026